Antibodies

<STRONG>Volume 1:-</STRONG> <STRONG>1.</STRONG> Concepts in Development of Manufacturing Strategies for Monoclonal Antibodies; <EM>B. Fish.</EM> <STRONG>2.</STRONG> Antibody Fragments: Production, Purification and Formatting for Therapeutic Applications; <EM>D.J. Glover,</EM> <EM>D.P. Humphreys.</EM> <STRONG>3.</STRONG> Large Scale Production of Therapeutic Antibodies: Considerations for Optimizing Product Capture and Purification; <EM>G.</EM> <EM>Kemp, P. O'Neil.</EM> <STRONG>4.</STRONG> Scale-Up of Antibody Purification. From Laboratory Scale to Production; <EM>L.R. Jacob, M. Frech.</EM> <STRONG>5.</STRONG> Purification of Antibody by Chromatographic Methods; <EM>C. Vandevyver, R. Freitag.</EM> <STRONG>6.</STRONG> Quality Control of Antibodies for Human Use; <EM>A. Richter, M. Jostameling, K.</EM> <EM>Müller, A. Herrmann, M. Pitschke.</EM> <STRONG>7.</STRONG> Expression of Human Anti Rh(D) Monoclonal Antibodies into Different Cell lines: Influence on their Functional Properties; <EM>C. de Romeuf, C. Gaucher, A. Glacet, S.</EM> <EM>Jorieux, P. Klein, D. Bourel.</EM> <STRONG>8.</STRONG> Monoclonal Antibody Production: Minimising Virus Safety Issues; <EM>J. Bray, M.K. Brattle.</EM> <STRONG>9.</STRONG> Contract Manufacturing of Biopharmaceutical Grade Antibodies; <EM>L.A. Van Der Pol,</EM> <EM>D.F. Westra.</EM> <STRONG>10.</STRONG> The Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies; <EM>D.B. Haughey, P.M. Jardieu.</EM> <STRONG>11.</STRONG> Regulatory and Legal Requirements for the Manufacture of Antibodies; <EM>L. Tsang.</EM> Index. <BR><STRONG>Volume 2:-</STRONG> <STRONG>1.</STRONG> Transgenic technology for monoclonal antibody production; <EM>S. Sensoli.</EM> <STRONG>2.</STRONG> Generation, engineering and production of human antibodies using HuCAL; <EM>R. Ostendorp, C. Frisch, M. Urban.</EM> <STRONG>3.</STRONG> Achieving appropriate glycosylation during the scaleup of antibody production; <EM>X.K. Deng, T. Shantha Raju, K.J. Morrow Jr.</EM> <STRONG>4.</STRONG> Approaches to devise antibody purification processes by chromatography; <EM>E.</EM> <EM>Boschetti.</EM> <STRONG>5.</STRONG> Novel HIV neutralizing antibodies selected from phage display libraries; <EM>M. Moulard, Mei-Yun Zhang, D.S. Dimitrov.</EM> <STRONG>6.</STRONG> Monoclonal and bispecific antibodies in combination with radiotherapy for cancer treatment; <EM>D. Azria, C. Larbouret, B. Robert, M. Ozsahin,</EM> <EM>J.B. Dubois, A. Pèlegrin.</EM> <STRONG>7.</STRONG> Antibodies, a potent tool to target genes into designated cells and tissues; <EM>F. Hirsch, O. Deas, G.</EM> <EM>Carvalho, A. Dürrbach, D. Thierry, A. Chapel.</EM> <STRONG>8.</STRONG> Intrabodies: development and application in functional genomics and therapy; <EM>A.</EM> <EM>Barberis, A. Auf Der Maur, K. Tissot, P. Lichtlen.</EM> <STRONG>9.</STRONG> Expression of recombinant antibodies by tumour cells: on road to anti-tumour therapy; <EM>E. Bonnin, J.-L. Teillaud.</EM> <STRONG>10.</STRONG> Antitumor antibodies: from research to clinic; <EM>S. Ménard, S.M. Pupa, M. Campiglio, E.</EM> <EM>Tagliabue.</EM> <STRONG>11.</STRONG> Macrophages for immunotherapy; <EM>D. Loirat, S. Jacod, A.</EM> <EM>Boyer, F. Auzelle, A. McAllister, J.-P. Abstado, J. Bartholeyns, D.</EM> <EM>Prigent.</EM> <STRONG>12.</STRONG> Future prospects in antibody engineering and therapy; <EM>S.</EM> <EM>Siberil, J.-L. Teillaud.</EM> Index.